Fate Therapeutics Inc. (FATE)

13.48
1.17 9.50
NASDAQ : Health Technology
Prev Close 12.31
Open 12.34
Day Low/High 12.34 / 13.50
52 Wk Low/High 2.52 / 14.45
Volume 1.15M
Avg Volume 600.90K
Exchange NASDAQ
Shares Outstanding 52.86M
Market Cap 650.68M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Fate Therapeutics Announces Initial Clinical Data Of FATE-NK100 For Recurrent Ovarian Cancer At The Innate Killer Summit 2018

Fate Therapeutics Announces Initial Clinical Data Of FATE-NK100 For Recurrent Ovarian Cancer At The Innate Killer Summit 2018

Stable Disease with Tumor Shrinkage Reported in Subject 2 Following Single Dose of NK100

Interesting FATE Put And Call Options For November 16th

Interesting FATE Put And Call Options For November 16th

Investors in Fate Therapeutics Inc saw new options begin trading this week, for the November 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Fate Therapeutics Announces Receipt Of CIRM Grant For Clinical Translation Of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy

Fate Therapeutics Announces Receipt Of CIRM Grant For Clinical Translation Of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy

$4.0 Million Awarded by CIRM to Support Advancement of First-of-Kind NK Cell Product Candidate derived from a Master Engineered iPSC Line

Fate Therapeutics Reaches Analyst Target Price

Fate Therapeutics Reaches Analyst Target Price

In recent trading, shares of Fate Therapeutics Inc have crossed above the average analyst 12-month target price of $9.40, changing hands for $10.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Fate Therapeutics Announces First Subject Treated With FATE-NK100 In DIMENSION Study For Advanced Solid Tumors

Fate Therapeutics Announces First Subject Treated With FATE-NK100 In DIMENSION Study For Advanced Solid Tumors

First Clinical Trial Investigating the Combination of Allogeneic Donor NK Cell Therapy and FDA-Approved Targeted Monoclonal Antibody Therapy for Solid Tumor Malignancies

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

Commit To Purchase Fate Therapeutics At $5, Earn 20% Annualized Using Options

Commit To Purchase Fate Therapeutics At $5, Earn 20% Annualized Using Options

Investors eyeing a purchase of Fate Therapeutics Inc shares, but cautious about paying the going market price of $6.38/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $5 strike, which has a bid at the time of this writing of 60 cents.

TheStreet Quant Rating: D (Sell)